Paxman AB (publ) announced that this week, important abstracts highlighting the use of cryotherapy in the prevention and management of adverse effects of chemotherapy treatment were presented by key international experts at the eminent international conference on supportive cancer care, the MASCC/AFSOS/ISOO 2024 Annual Meeting in Lille, Paris. The company presented the latest results from the limb cryocompression clinical trials currently in progress to help prevent the debilitating and often dose-limiting side-effect of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients receiving taxane-based chemotherapy. The company updated the audience of the latest multi-centre trial results from Singapore, utilising the novel Paxman Limb Cryocompression Device, currently in development.

The Single-arm phase I-II study from multiple sites in Singapore evaluated the safety and efficacy of a novel wearable limb cryocompression device. The company reported data from 47 patients that were included in the Singapore trial to date. A majority of the patients (79%) completed all planned treatments with cryocompression.

Limb cooling was well tolerated at 11°C, even with concurrent scalp cooling (of which a third of the patients underwent concomitant scalp and limb cooling). More than half (57%) of patients completed all planned treatments without any dose reduction or delay of taxane chemotherapy and impressively only 8% of patients required dose modification of their chemotherapy drugs due to CIPN. Importantly 65% of patients did not experience CIPN, whilst 32% developed Grade 1 CIPN; 50% of which were transient.

Only 15% of patients experienced clinically meaningful CIPN at the end of chemotherapy treatment with only 1 patient developing grade 2 CIPN. The study concludes that the use of limb cryocompression: is safe and well-tolerated in patients receiving taxane-based chemotherapy; can be safely administered with scalp cooling therapy; shows promising data in preventing taxane-based CIPN with no significant change in sensory scores reported and facilitates the effective dose delivery of taxane-based chemotherapy.